Naproxen Sodium; Sumatriptan Succinate Patent Expiration

Naproxen Sodium; Sumatriptan Succinate is Used for the treatment of migraines. It was first introduced by Currax Pharmaceuticals Llc in its drug Treximet on Apr 15, 2008. 4 different companies have introduced drugs containing Naproxen Sodium; Sumatriptan Succinate.


Naproxen Sodium; Sumatriptan Succinate Patents

Given below is the list of patents protecting Naproxen Sodium; Sumatriptan Succinate, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Treximet US7332183

(Pediatric)

Multilayer dosage forms containing NSAIDs and triptans Apr 02, 2026 Currax
Treximet US7332183 Multilayer dosage forms containing NSAIDs and triptans Oct 02, 2025 Currax
Treximet US5872145

(Pediatric)

Formulation of 5-HT agonist and NSAID for treatment of migraine Feb 14, 2018

(Expired)

Currax
Treximet US6060499

(Pediatric)

Anti-migraine methods and compositions using 5-HT agonists with long-acting NSAIDs Feb 14, 2018

(Expired)

Currax
Treximet US6586458

(Pediatric)

Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs Feb 14, 2018

(Expired)

Currax
Treximet US8022095

(Pediatric)

Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs Feb 14, 2018

(Expired)

Currax
Treximet US5872145 Formulation of 5-HT agonist and NSAID for treatment of migraine Aug 14, 2017

(Expired)

Currax
Treximet US6060499 Anti-migraine methods and compositions using 5-HT agonists with long-acting NSAIDs Aug 14, 2017

(Expired)

Currax
Treximet US6586458 Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs Aug 14, 2017

(Expired)

Currax
Treximet US8022095 Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs Aug 14, 2017

(Expired)

Currax



A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Naproxen Sodium; Sumatriptan Succinate's patents.

Given below is the list recent legal activities going on the following patents of Naproxen Sodium; Sumatriptan Succinate.

Activity Date Patent Number
Patent litigations
Expire Patent 28 Oct, 2019 US8022095
Payment of Maintenance Fee, 12th Year, Large Entity 19 Aug, 2019 US7332183
Maintenance Fee Reminder Mailed 13 May, 2019 US8022095
Request for Trial Denied 06 May, 2016 US7332183
Petition Requesting Trial 12 Nov, 2015 US7332183
Email Notification 04 Sep, 2012 US7332183
Change in Power of Attorney (May Include Associate POA) 04 Sep, 2012 US7332183
Correspondence Address Change 01 Sep, 2012 US7332183
Email Notification 21 Sep, 2011 US8022095
Recordation of Patent Grant Mailed 20 Sep, 2011 US8022095


Naproxen Sodium; Sumatriptan Succinate's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List



Naproxen Sodium; Sumatriptan Succinate Generics

Several generic applications have been filed for Naproxen Sodium; Sumatriptan Succinate. The first generic version for Naproxen Sodium; Sumatriptan Succinate was by Aurobindo Pharma Ltd and was approved on Feb 15, 2018. And the latest generic version is by Rising Pharma Holdings Inc and was approved on Sep 4, 2018.

Given below is the list of companies who have filed for Naproxen Sodium; Sumatriptan Succinate generic.


1. AUROBINDO PHARMA LTD

Aurobindo Pharma Ltd has filed for 1 generic for Naproxen Sodium; Sumatriptan Succinate. This 500mg;eq 85mg base version comes by the name SUMATRIPTAN AND NAPROXEN SODIUM. Given below are the details of the strengths of this generic introduced by Aurobindo Pharma Ltd.

Strength Dosage Form Availability Application Pathway TE code Launch Date
500MG; EQ 85MG BASE tablet Prescription ORAL AB Feb 15, 2018


2. RISING

Rising Pharma Holdings Inc has filed for 1 generic for Naproxen Sodium; Sumatriptan Succinate. This 500mg;eq 85mg base version comes by the name SUMATRIPTAN AND NAPROXEN SODIUM. Given below are the details of the strengths of this generic introduced by Rising.

Strength Dosage Form Availability Application Pathway TE code Launch Date
500MG; EQ 85MG BASE tablet Prescription ORAL AB Sep 4, 2018


3. SUN PHARM

Sun Pharmaceutical Industries Ltd has filed for 1 generic for Naproxen Sodium; Sumatriptan Succinate. This 500mg;eq 85mg base version comes by the name SUMATRIPTAN AND NAPROXEN SODIUM. Given below are the details of the strengths of this generic introduced by Sun Pharm.

Strength Dosage Form Availability Application Pathway TE code Launch Date
500MG; EQ 85MG BASE tablet Prescription ORAL AB Jul 20, 2018